Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma (Q34225751)

31 July 2017

title

Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma (English)

1 reference

31 July 2017

1 reference

1 reference

16

Kazuaki Chayama

1 reference

31 July 2017

12

Michio Imamura

1 reference

31 July 2017

2

Hiroshi Aikata

1 reference

31 July 2017

5

Tomokazu Kawaoka

1 reference

31 July 2017

14

Yoshiiku Kawakami

1 reference

31 July 2017

15

Shoichi Takahashi

1 reference

31 July 2017

Soo Cheol Jeong

1

1 reference

31 July 2017

Yoshio Katamura

3

1 reference

31 July 2017

Takahiro Azakami

4

1 reference

31 July 2017

Hiromi Saneto

6

1 reference

31 July 2017

Kiminori Uka

7

1 reference

31 July 2017

Nami Mori

8

1 reference

31 July 2017

Shintaro Takaki

9

1 reference

31 July 2017

Hideaki Kodama

10

1 reference

31 July 2017

Koji Waki

11

1 reference

31 July 2017

Hiroo Shirakawa

13

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 October 2007

1 reference

World Journal of Gastroenterology

31 July 2017

published in

1 reference

31 July 2017

volume

13

1 reference

31 July 2017

issue

40

1 reference

31 July 2017

page(s)

5343-5350

1 reference

Hepatitis C virus core protein promotes proliferation of human hepatoma cells through enhancement of transforming growth factor expression via activation of nuclear factor- B

31 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171324

Molecular basis of hepatitis C virus-associated hepatocarcinogenesis: lessons from animal model studies

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171324

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171324

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171324

Pegylation: a novel process for modifying pharmacokinetics

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171324

Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171324

Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171324

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171324

Anti-oncogenic and oncogenic potentials of interferon regulatory factors-1 and -2

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171324

Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171324

Characteristic difference of hepatocellular carcinoma between hepatitis B- and C- viral infection in Japan

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171324

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171324

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171324

Signal transduction by interferon-alpha through arachidonic acid metabolism

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171324

Effects of recombinant alpha-interferon-gelatin conjugate on in vivo murine tumor cell growth.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171324

Biological activities of recombinant murine interferons alpha 1 and alpha 4: large difference in antiproliferative effect

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171324

Effect of long-term postoperative interferon therapy on intrahepatic recurrence and survival rate after resection of hepatitis C virus-related hepatocellular carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171324

Low-dose, long-term, intermittent interferon-alpha-2b therapy after radical treatment by radiofrequency ablation delays clinical recurrence in patients with hepatitis C virus-related hepatocellular carcinoma

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171324

Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171324

Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171324

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171324

Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171324

Peginterferon alfa-2a in patients with chronic hepatitis C.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171324

Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171324

Effects of continuous hepatitis with persistent hepatitis C viremia on outcome after resection of hepatocellular carcinoma.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171324

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171324

Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171324

Risk factors for tumor recurrence and prognosis after curative resection of hepatocellular carcinoma

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171324

Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4171324

Risk factors for hepatocellular carcinoma among patients with chronic liver disease

28 October 2018

1 reference

12 December 2020

Cooperation of the tumour suppressors IRF-1 and p53 in response to DNA damage

1 reference

12 December 2020

Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C

1 reference

12 December 2020

alpha-Interferon in the treatment of chronic viral hepatitis: effects on fibrogenesis serum markers

1 reference

12 December 2020

Interferon alpha inhibits intrahepatic recurrence in hepatocellular carcinoma with chronic hepatitis C: a pilot study

1 reference

12 December 2020

Incidence and factors associated with intrahepatic recurrence following resection of hepatocellular carcinoma

1 reference

12 December 2020

Prognosis of recurrent hepatocellular carcinoma: a 10-year surgical experience in Japan

1 reference

12 December 2020

Changes in serum fibrogenesis markers during interferon therapy for chronic hepatitis type C

1 reference

12 December 2020

Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma

1 reference

12 December 2020

Differential effects of gamma-interferon on collagen and fibronectin gene expression

1 reference

12 December 2020

The general rules for the clinical and pathological study of primary liver cancer. Liver Cancer Study Group of Japan

1 reference

12 December 2020

Interferon: a cytotoxic T lymphocyte differentiation signal

1 reference

12 December 2020

Identifiers

DOI

10.3748/WJG.V13.I40.5343

1 reference

31 July 2017

1 reference

31 July 2017

1 reference